Log In Sign up
The largest database of trusted experimental protocols

Mimvista work station

Manufactured by MIM Software
Visit Supplier
Sourced in United States

The MIMVista workstation is a software platform designed for medical imaging analysis and visualization. It provides tools for viewing and processing medical images, such as CT, MRI, and PET scans, to assist healthcare professionals in diagnosis and treatment planning.

Automatically generated - may contain errors

Lab products found in correlation

Vue point fx, by GE Healthcare (1 mentions) Discovery mv690, by GE Healthcare (1 mentions)

5 protocols using mimvista work station

1

Fluciclovine-based PET-CT Imaging Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Fluciclovine preparation was completed as earlier reported under IND (Investigational New Drug Application) 72,437.15 (link) Patients ingested oral contrast medium after at least 4 hours of fasting. An initial cT with a 3.75 mm slice thickness and 3.25 mm spacing was completed to correct attenuation (approximately 100 mA). Next a mean ± SD of 364.1 ± 37.7 MBq (9.84 ± 1.02 mCi) intravenous fluciclovine was administered. Five minutes after injection the patient underwent dual time point PET from pelvis to diaphragm at 2.5 minutes per bed position for 4 table positions. Scanning was completed on a Discovery MV690 PET-CT scanner (GE Healthcare, Wauwatosa, Wisconsin). Images were reconstructed with an iterative technique using a VUE Point Fx (GE Healthcare) with 3 iterations, 24 subsets and a filter cutoff of 6.4 mm. Images were transferred to a MIMVista work station (MIM Software, Cleveland, Ohio) for interpretation.
Fei B., Abiodun-Ojo O.A., Akintayo A.A., Akin-Akintayo O., Tade F., Nieh P.T., Master V.A., Alemozaffar M., Osunkoya A.O., Goodman M.M, & Schuster D.M. (2019). Feasibility and Initial Results: Fluciclovine Positron Emission Tomography/Ultrasound Fusion Targeted Biopsy of Recurrent Prostate Cancer. The Journal of urology, 202(2), 413-421.
+ Open protocol
+ Expand
2

Quantitative PET/CT and MRI Breast Tumor Analysis

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
A specialist in nuclear medicine with 11 years of PET experience reviewed the FDG PET/CT images on a MIMvista workstation (ver. 6.5; MIM Software Inc, Cleveland, OH). All metabolic parameters were measured from the tumor volume segmented by a gradient-based method, as previously described.[22 (link),23 (link)] A gradient segmentation method is available in the MIMvista software with an operator-defined starting point near the center of the breast tumor lesion. Once the primary target lesion was segmented, SUVmax, mean standardized uptake value (SUVmean), MTV, and TLG were calculated automatically by the MIMvista software (Fig. 1). TLG was calculated by multiplying the SUVmean by the MTV. All SUVs were estimated based on injected dose and body weight.
All MR images were reviewed by a radiologist with 9 years of experience in interpreting breast imaging data. The lesion size was measured as the longest diameter of the lesion on the MIP image using a picture archiving and communication system workstation with electronic calipers. For multiple lesions, the longest diameter of each lesion was recorded separately and the sum of the lesions was calculated.
An Y.S., Kang D.K., Jung Y, & Kim T.H. (2017). Volume-based metabolic parameter of breast cancer on preoperative 18F-FDG PET/CT could predict axillary lymph node metastasis. Medicine, 96(45), e8557.
+ Open protocol
+ Expand
3

Fluciclovine PET-CT Imaging Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Fluciclovine preparation was completed as earlier reported [15 (link), 16 (link)]. Patients fasted for at least 4 hours following which oral contrast was given and scanning completed on a GE Discovery MV690 PET-CT scanner (GE Healthcare, Wauwatosa, WI). An initial CT scan was completed for attenuation correction (approximately 100 mAs) and 370.0±13.0 MBq (10.0±0.35mci) of fluciclovine was then intravenously infused via pump over two minutes, followed by a 3 minute wait to allow for blood pool clearance. A 2.5 min/bed emission acquisition from pelvis to diaphragm (5–15 minute) was performed and then immediately repeated (15.5–25.5 min). Images were reconstructed with iterative technique (VUE Point Fx; 3 iterations, 24 subsets. filter cutoff 6.4 mm, GE Healthcare, Wauwatosa, WI) and transferred to a MIMVista work station (MIM Software; Cleveland, OH) for interpretation.
Akin-Akintayo O., Tade F., Mittal P., Moreno C., Nieh P.T., Rossi P., Patil D., Halkar R., Fei B., Master V., Jani A.B., Kitajima H., Osunkoya A.O., Ormenisan-Gherasim C., Goodman M.M, & Schuster D.M. (2018). Prospective Evaluation of Fluciclovine (18F) PET-CT and MRI in Detection of Recurrent Prostate Cancer in Non-prostatectomy Patients. European journal of radiology, 102, 1-8.
+ Open protocol
+ Expand
4

Standardized Liver SUL Measurement

Check if the same lab product or an alternative is used in the 5 most similar protocols
All FDG PET/CT scans were independently interpreted on a MIMvista workstation (software version 5.2; MIM Software Inc. Cleveland, OH) by two readers, who are both board certified Nuclear Medicine physicians. PET, CT, and fused PET/CT images were reviewed in the axial, coronal, and sagittal planes. Liver SULmean values were measured in the following three separate areas within the right lobe of the liver: (a) the right lobe above the portal vein (segments VII and VIII), (b) below the level of the portal vein in the right lower lobe (segments V and VI), and (c) at the level of the right portal vein (straddling segments V through VIII) (Figure 1). Spherical 30 mm diameter VOI's were placed at these three locations based on the CT and cross-referenced with the PET to assure that the VOI's were within the metabolic boundaries of the right liver. The right lobe of the liver was used because it is easier to draw the ROI at different levels, giving its larger size and it is the most common site used in clinical practice [16 (link), 20 (link), 24 (link), 25 (link)].
Chirindel A., Alluri K., Tahari A., Chaudhry M., Wahl R., Lodge M, & Subramaniam R. (2015). Liver SULmean at FDG PET/CT: Effect of FDG uptake time. Clinical nuclear medicine, 40(1), e17-e22.
+ Open protocol
+ Expand
5

Imaging Guided Prostate Cancer Recurrence

Check if the same lab product or an alternative is used in the 5 most similar protocols
Image interpretation was done on a MIMVista Workstation (MIM Software Inc, OH, USA). Image interpretation was done independently by two experienced board-certified nuclear medicine physicians each with more than 20-year experience. Discrepancies were resolved by consensus read. The interpreters were blinded to the patients’ clinical history including PSA level and findings on the prior conventional imaging modalities. Areas of increased 18F-fluciclovine uptake above background activity not corresponding to typical physiological uptake or its variants were considered pathological and in favor of PCa recurrence. The maximum standardized uptake value (SUVmax) of the recurrent lesion and the diameter (long and short axis dimensions) of lymph nodal recurrent lesions were determined and recorded. The recurrent lesions were classified as prostate (prostate bed, seminal vesicles, lateral resection margins, or vesicourethral anastomosis), pelvic (pelvic lymph nodes) or extrapelvic (outside of the standard field of pelvic SRT including skeletal, visceral, and extra-pelvic lymph nodes) recurrence.
Lawal I.O., Marcus C., Schuster D.M., Goyal S., Adediran O.A., Dhere V.R., Joshi S.S., Abiodun-Ojo O.A., Master V.A., Patel P.R., Fielder B., Goodman M., Shelton J.W., Kucuk O., Hershatter B., Halkar R.K, & Jani A.B. (2023). Impact of 18F-fluciclovine PET/CT findings on failure-free survival in biochemical recurrence of prostate cancer following salvage radiation therapy. Clinical nuclear medicine, 48(4), e153-e159.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!